Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(12 sites)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Peking University Third Hospital, Beijing

Sichuan Cancer Hospital, Chengdu

Fujian Province Cancer Hospital, Fuzhou

Guizhou Cancer Hospital, Guiyang

Zhejiang Cancer Hospital, Hangzhou

Jiangxi Cancer Hospital, Nanchang

The First Affiliated Hospital of Guangxi Medical University, Nanning

Fudan University Shanghai Cancer Center, Shanghai

Zhongnan Hospital of Wuhan University, Wuhan

Xijing Hospital, Xi'an

The First Affiliated Hospital of Xiamen University, Xiamen